New Drug Approvals Archive

Get news by email or subscribe to our news feeds.

September 2006

September 15

Noxafil (posaconazole)

Date of Approval: September 15, 2006
Company: Schering-Plough Corporation
Treatment for: Aspergillosis -- Invasive, Candidemia, Oral Thrush

Noxafil is a triazole antifungal agent indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age and older who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.

Noxafil (posaconazole) FDA Approval History

September 19

Verdeso (desonide) Foam

Date of Approval: September 19, 2006
Company: Connetics Corporation
Treatment for: Dermatitis

Verdeso (desonide) Foam is a low-potency topical steroid formulated in VersaFoam emulsion foam drug delivery vehicle for the treatment of mild-to-moderate atopic dermatitis.

Verdeso (desonide) FDA Approval History

September 21

Travatan Z (travoprost) Ophthalmic Solution

Date of Approval: September 21, 2006
Company: Alcon, Inc.
Treatment for: Glaucoma

Travatan Z (travoprost) is a new formulation of Travatan solution in which benzalkonium chloride is replaced with Sofzia, a robust ionic buffered preservative system that is gentle to the ocular surface. Travatan Z is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, who are intolerant of or insufficiently responsive to other intraocular pressure lowering medications.

Travatan Z (travoprost) FDA Approval History

September 25

Fentora (fentanyl) Buccal Tablets - formerly OraVescent Fentanyl

Date of Approval: September 25, 2006
Company: Cephalon, Inc.
Treatment for: Pain

Fentora is an effervescent buccal formulation of the potent opioid analgesic fentanyl, indicated for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Fentora (fentanyl) FDA Approval History

September 27

Vectibix (panitumumab) Injection

Date of Approval: September 27, 2006
Company: Amgen
Treatment for: Colorectal Cancer

Vectibix (panitumumab) is a recombinant, human IgG2 kappa monoclonal antibody indicated for the treatment of patients with epidermal growth factor receptor- (EGFr) expressing metastatic colorectal cancer after disease progression on, or following fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.

Vectibix (panitumumab) FDA Approval History

September 28

Pylera (bismuth subcitrate potassium, metronidazole and tetracycline) Capsules - formerly Helizide

Date of Approval: September 28, 2006
Company: Axcan Pharma Inc.
Treatment for: Helicobacter pylori Infection

Pylera (bismuth subcitrate potassium, metronidazole and tetracycline) is a 3-in-1 capsule triple therapy indicated for the eradication of Helicobacter pylori, a bacterium now recognized as being the main cause of gastric and duodenal ulcers.

Pylera (bismuth subcitrate potassium, metronidazole and tetracycline) FDA Approval History

November 26

Noxafil (posaconazole)

New Dosage Form Approved: November 25, 2013

Noxafil (posaconazole) FDA Approval History

March 14

Noxafil (posaconazole)

New Dosage Form Approved: March 13, 2014

Noxafil (posaconazole) FDA Approval History

Hide
(web2)